Navigation Links
Palatin Technologies Announces Third Quarter Fiscal Year 2013 Results and Update on Development of Bremelanotide for Female Sexual Dysfunction
Date:5/14/2013

9,6295,95537,01728,229Interest expense

(1,103)(1,830)(4,746)(6,650)Increase in fair value of warrants

--(7,069,165)-Gain on disposition of supplies and equipment

-1,7004,6204,700Total other income (expense), net

8,5265,825(7,032,274)26,279Loss before income taxes

(4,015,258)(6,020,702)(17,897,334)(13,068,118)Income tax benefit

--1,753,2081,068,233NET LOSS

$
(4,015,258)$
(6,020,702)$
(16,144,126)$
(11,999,885)Basic and diluted net loss per common share

$
(0.04)$
(0.17)$
(0.17)$
(0.34)Weighted average number of common shares

outstanding used in computing basic and diluted net

loss per common share

106,424,44334,900,59194,754,78934,900,591 PALATIN TECHNOLOGIES, INC.and SubsidiaryConsolidated Balance Sheets(unaudited)March 31, 2013June 30, 2012ASSETSCurrent assets:Cash and cash equivalents

$
23,537,053$
3,827,198Short-term investments

5,998,740-Accounts receivable

-27,631Restricted cash

-350,000Prepaid expenses and other current assets

488,185532,010Total current assets

30,023,9784,736,839Property and equipment, net

307,020318,653Other assets

58,337324,992Total assets

$
30,389,335$
5,380,484LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Capital lease obligations

$
23,591$
22,277Accounts payable 

733,443294,894Accrued expenses

1,986,2402,706,496Accrued compensation

-433,333Total current liabilities

2,743,2743,457,000Capital lease obligations 

2,04819,909Deferred rent

44,76472,677Total liabilities

2,790,0863,549,586Stockholders' equity:Preferred stock of $0.01 par value – authorized 10,000,000 shares;Series A Convertible; issued and outstanding 4,697 shares as

of March 31, 2013 and 4,997 as of June 30, 2012 

4750Common stock of
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Palatin Technologies, Inc. To Report Fiscal Year 2013 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2013
2. Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-Specific Peptides for Sexual Dysfunction
3. Palatin Technologies To Present At The 25th Annual ROTH Conference
4. Palatin Technologies, Inc. To Present At The Cowen & Company 33rd Annual Health Care Conference
5. Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on February 14, 2013
6. Palatin Technologies, Inc. To Report Fiscal Year 2013 Second Quarter Results; Teleconference and Webcast to be held on February 14, 2013
7. Palatin Technologies, Inc. to Present at 15th Annual BIO CEO & Investor Conference
8. Palatin Technologies, Inc. to Present at the 24th Annual Piper Jaffray Healthcare Conference
9. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on November 14, 2012
10. Palatin Technologies, Inc. To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
11. Palatin Technologies, Inc. To Report Fiscal Year 2013 First Quarter Results; Teleconference and Webcast to be held on November 14, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today ... odour control projects in North America , the ... . "Bidding activity in 2015 continues to be robust" ... high volume year for bidding in 2014, we are pleased to ... orders reflect the organization,s renewed focus on select market segments where ...
(Date:3/3/2015)... , March 3, 2015 Adaptive Biotechnologies ... CFO, is joining its Board of Director as Chair ... officer at Zillow Group, Chad oversees all finance, treasury ... built the company,s core finance, treasury and accounting functions, ... and nine acquisitions. In 2013, he was named Puget ...
(Date:3/3/2015)... March 3, 2015 Fried, Frank, Harris, Shriver ... Lewis has joined the Firm as a partner ... New York office. Mr. Lewis ... as well as other intellectual property and general litigation. ... Lewis represents both plaintiffs and defendants in a range ...
(Date:3/3/2015)... , March 3, 2015  Thingee Corporation, a software ... delivering a presentation entitled, "Technology Adoption: Making Reps, Lives ... through Innovations and Technology ,  in Deerfield ... to 13, 2015. Audiences looking to learn how technology ... want to be in the audience for the Thingee ...
Breaking Biology Technology:Adaptive Biotechnologies adds Chad Cohen, Zillow Group CFO, to Board of Directors 2Leading Patent Attorney Jeffrey Lewis Joins Fried Frank's Intellectual Property Litigation Practice 2Leading Patent Attorney Jeffrey Lewis Joins Fried Frank's Intellectual Property Litigation Practice 3Thingee to present at 11th Annual Synergistix Users Conference 2
... Sept. 8 Don Margolis, Chairman of,The Repair ... based in,Bangkok, Thailand told The Wall Street Transcript ... future profits inside the stem cell,research sector will ... five years, even for,companies specializing in Repair Stem ...
... 7th International ... Symposium on Uveitis in Germany, ZURICH, Switzerland, Sept. ... today announced that the,company has successfully completed its Phase I ... indications. In,April 2008, ESBATech initiated the Phase I study designed ...
... RNA levels, following 4 weeks of treatment with R7128 1500mg BID with Pegasys(R) plus ... Copegus(R) -, ... ... 8 Pharmasset, Inc.,(Nasdaq: VRUS ) announces the preliminary results of the fourth cohort ...
Cached Biology Technology:Stem Cell Profits Five Years Away, Says Repair Stem Cell Institute Chairman to The Wall Street Transcript 2ESBATech Announces Successful Completion of Phase I Clinical Study for Lead Antibody Fragment in Ophthalmic Indications 2Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 2Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 3Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 4Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 5Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders 6
(Date:3/2/2015)... HUNTSVILLE, Ala. , March 2, 2015 /PRNewswire/ ... transaction processing. Data protection company Tharon Rankins Enterprises ... product that provides an ultra-safe way for businesses ... as their financial transactions. Beconux ... by Tharon Rankins Enterprises. Functioning similarly to an ...
(Date:2/24/2015)... This report analyzes the worldwide markets for Iris ... for the US, Canada , ... Asia-Pacific , Middle East , and ... are provided for the period 2013 through 2020. Also, a ... and analytics are derived from primary and secondary research. Company ...
(Date:2/23/2015)... , Feb. 23, 2015 NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the growing ... provisional patent 62114357 for DISTRIBUTED VOICE DIRECTED ... NXT-ID introduces a new groundbreaking payment method. Payment accounts ... account may only be accessed if both the speech ...
Breaking Biology News(10 mins):Personal Data Protection Company Launches New Product 2World Iris Biometrics Industry 2World Iris Biometrics Industry 3World Iris Biometrics Industry 4World Iris Biometrics Industry 5World Iris Biometrics Industry 6World Iris Biometrics Industry 7World Iris Biometrics Industry 8World Iris Biometrics Industry 9World Iris Biometrics Industry 10World Iris Biometrics Industry 11NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3
... 2013 Disulfiram was the first medication approved for ... works, at least in part, by preventing the metabolism ... in the body quickly cause unpleasant symptoms, including nausea, ... a very strong incentive to avoid drinking. ...
... the fate of the original Otom inhabitants of Xaltocan, ... unknown. Researchers have long wondered whether they assimilated with ... to new anthropological research from The University of Texas ... the answers may lie in DNA. Following this line ...
... Thailand and Morocco have found that DHEA-S may prevent ... patients. In a report appearing in the February 2013 ... they describe how a network of steroid molecules found ... infection leading to brain damage. This suggests that treatment ...
Cached Biology News:Disulfiram: New support for an old addiction drug 2Aztec conquest altered genetics among early Mexico inhabitants, new DNA study shows 2A 'neurosteroid' found to prevent brain injury caused by HIV/AIDS 2
...
...
Assay Diluent, 10 L...
... Immunogen: Synthetic peptide derived from ... junctophilin-3. Specificity: Specific for the ... Reactivity: Mouse (positive controls: mouse ... heart tissues). Applications: Western blotting ...
Biology Products: